Szarkóma: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• KRAS 10
• TP53 1
• PD-1 19
• PD-L1 9
• PI3K 0
• AKT 0
• NTRK 2
• mTOR 0
• STAT3 0
• MAPK 0
• CTNNB1 0
• MDM2 2
• BRAF 3
• MYC 0
• RAS 3
• ERK 0
• JNK 0
• VEGF 3
• ALK 2
• B7-H3 10
• STING 1
• CDK4/6 3
• EGFR 1
• JAK 1
• PARP 4
• YAP 0
• IDH 2
• FGFR 2
• HER2 5
• MEK 2
• CTLA-4 5
• NRAS 0
• GPX4 0
• HIF-1 0
• PTEN 0
• EZH2 0
• PPAR 0
• METTL3 1
• NF1 5
• AMPK 0
• GPC3 5
• PDGFR 3
• ABL1 0
• CD47 0
• COX-2 0
• ROS1 2
• AXL 0
• CDKN2A 0
• CXCR4 0
• IL-15 4
• MMP-9 0
• PRAME 1
• PSMA 0
• RET 0
• BCL-2 0
• BRCA2 1
• CD19 2
• FLT3 0
• FTO 0
• HDAC 0

34+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NEI · R43

  Novel gene mutation agnostic small molecule to treat retinitis pigmentosa

  Mitochem Therapeutics Inc.· Charleston, Egyesült Államok· 320 790 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NCI · F31

  Assessing autophagic dependencies in the context of RAS inhibition in pancreatic ductal adenocarcinoma

  Univ of North Carolina Chapel Hill· Chapel Hill, Egyesült Államok· 37 011 USD awarded in fiscal year 2026· until 2029. szept.

• NIH NIA · R01

  Synapse repair in Alzheimer's disease and related dementias

  Buck Institute for Research on Aging· Novato, Egyesült Államok· 785 081 USD awarded in fiscal year 2026· until 2031. júl.

• NIH NINDS · R43

  Development of an Anti-Nerve Growth Factor Active Immunotherapy for Difficult-to-Manage Pain

  Twilight Bioscience, Inc.· Topsfield, Egyesült Államok· 350 188 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · R16

  Mechanisms of lymphoma cell dissemination to the brain

  North Park University· Chicago, Egyesült Államok· 162 527 USD awarded in fiscal year 2026· until 2030. aug.

• European Commission (Horizon Europe) · HORIZON-RIA

  immunoTHErapies targeting neOgenes in paeDiatric and adOlescent saRcomAs (THEODORA)

  Institut Curie· Paris, Franciaország· EU contribution 8 712 800 EUR· until 2032. febr.· 5 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Primary bone cancer scaffolds as controlled release non-viral gene delivery platforms (PANACEA)

  Royal College of Surgeons in Ireland· Dublin 2, Írország· EU contribution 2 302 626 EUR· until 2031. máj.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Self-Assembling, Self-Monitoring, Multi-Stimuli-Responsive Implants for the Minimally Invasive Treatment of Critical-Size Defects (Morphogenesis)

  Fundacion Imdea Materiales· Getafe, Spanyolország· EU contribution 194 075 EUR· until 2028. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the role of RNA-binding proteins in telomere replication stress and alternative lengthening of telomeres (RBPandALT)

  The Francis Crick Institute Limited· London, Egyesült Királyság· EU contribution 260 348 EUR· until 2028. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  Pioneering antibody-drug conjugates targeting the tumour microenvironment to deliver transformative new therapies in oncology (ONCO-DART)

  Oncomatryx Biopharma Sa· Derio, Spanyolország· EU contribution 2 499 376 EUR· until 2027. okt.

  The disease is named only in the funder's project summary, not in the title.

10 of 1624 running projects, newest first. Listed amounts together: 944,4 M USD + 86,8 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

  NCT05580588· Shanghai Pharma Biotherapeutics USA Inc.· Frissítve: 2025. jún. 13.

  “Although no safety issues with SPH4336 were identified, efficacy in liposarcoma patient was less than anticipated.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

  NCT05905341· Pfizer· Frissítve: 2023. nov. 8.

  “This decision was based on business considerations and not due to specific safety reasons or a request from a regulatory authority.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

  NCT04557449· Pfizer· Forrás

• Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

  NCT03709680· Pfizer· Forrás

• Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

  NCT04438824· Memorial Sloan Kettering Cancer Center· Forrás

• A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

  NCT04238819· Eli Lilly and Company· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 41
• Organoids 10
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 11
• Gene Expression Profiling 99
• Sequence Analysis, RNA 21
• Whole Genome Sequencing 4
• Exome Sequencing 14
• Proteomics 31
• Metabolomics 7
• Mass Spectrometry 5
• Flow Cytometry 52
• Immunohistochemistry 186
• Liquid Biopsy 12
• Circulating Tumor DNA 19
• Xenograft Model Antitumor Assays 153
• Positron-Emission Tomography 19
• Magnetic Resonance Imaging 198
• Machine Learning 29
• Deep Learning 16
• Cohort Studies 30
• Genome-Wide Association Study 2

• Leveraging Single-Cell RNA Sequencing to Characterize Murine Ewing Sarcoma Xenografts.

  Methods Mol Biol, 2027. jan.

• Molecular Approaches to Diagnosis in Ewing Sarcoma: Targeted RNA Sequencing.

  Methods Mol Biol, 2027. jan.

• When morphology suggests a fusion: A pathology-centered escalation framework from histology and immunohistochemistry to RNA sequencing.

  Ann Diagn Pathol, 2026. aug.

• Deep learning models for cell cycle phase prediction from single-cell RNA sequencing data.

  Brief Bioinform, 2026. júl.

• Validation of the Transcription Association Chromosomal Instability Index Biomarker on RNA Sequencing in Soft Tissue Sarcomas.

  JCO Precis Oncol, 2026. jún.

• Detecting Rare ALK Gene Fusions in Unclassified Spindle Cell Lung Tumors Using Anchored Multiplex PCR/Targeted RNA Next-Generation Sequencing.

  Genes Chromosomes Cancer, 2026. jún.

• RNA-based next-generation sequencing strategy for screening MDM2-amplified sarcomas.

  Sci Rep, 2026. ápr.

• Molecular Characterization of Soft Tissue Sarcomas Using RNA-Based Next-Generation Sequencing.

  Int J Mol Sci, 2026. márc.

• Genomic Landscape of Myoepithelial Carcinoma Tumors.

  Oral Dis, 2026. márc.

• Clinical Impact of Integrating RNA-Based Next-Generation Sequencing Into the Diagnostic Evaluation of Soft Tissue Sarcomas: Insights From a Single-Center Multidisciplinary Workflow.

  JCO Glob Oncol, 2026. márc.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.